Showing 3961-3970 of 9138 results for "".
- Meta-Analysis: Similar AK Clearance With PDT and Cryotherapyhttps://practicaldermatology.com/news/meta-analysis-finds-similar-ak-clearance-with-pdt-and-cryotherapy/2486675/A recent systematic review and meta-analysis suggested comparable efficacy and safety of photodynamic therapy (PDT) and cryotherapy for lesion clearence in actinic keratosis (AK). The analysis, published in the Journal of
- Prediction Model Suggests Reduced Need for Laryngoscopy in Pemphigus Vulgarishttps://practicaldermatology.com/news/model-suggests-reduced-need-for-laryngoscopy-in-pemphigus-vulgaris/2486535/A new proposed clinical prediction model may identify low-risk patients who can safely defer laryngoscopy, reducing unnecessary procedures. Researchers for the retrospective cohort study from a tertiary dermatology center eval
- Early Inflammatory Signals May Precede Alopecia Areata Diagnosishttps://practicaldermatology.com/news/early-inflammatory-signals-may-precede-alopecia-areata-diagnosis/2486446/Data from a new systematic review presented at the 2026 American Academy of Dermatology Annual Meeting indicated a consistently elevated neutrophil-to-lymphocyte ratio (NLR) in alopecia areata (AA).Investigators used data from PubMed, Embase, and Cochrane
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://practicaldermatology.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://practicaldermatology.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://practicaldermatology.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee